Prevention of graft-versus-host disease in HLA-matched bone marrow transplantation for malignant diseases: a multicentric study of 62 patients using 3-pan-T monoclonal antibodies and rabbit complement.
- 1 March 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (3) , 426-435
- https://doi.org/10.1200/jco.1987.5.3.426
Abstract
In order to evaluate the effectiveness and reproducibility of T cell depletion in human leukocyte antigen (HLA)-mathched bone marrow graft to prevent graft-vs.-host disease (GVHD), our multicentric study (nine different centers) investigated 62 consecutive patients with poor prognosis leukemia or hematosarcoma from June 1984 to November 1985. The data were updated October 1, 1986, and the mean follow-up was 18 .+-. 4.3 months. T cells were depleted with a combination of 3-pan-T cell monoclonal antibodies (CD2 "D66"; CD5 "A50"; CD7 "121") with a single incubation of rabbit complement (C''). The average number of T cells infused was 0.66 .times. 106 .+-. 0.56/kg body weight. Twenty-six patients received chemoprophylaxis for GVHD, 16 received methotrexate, and ten received cyclosporin A. Only a single case of severe (> grade II) GVHD was observed, yet the incidence of graft failure was 19%. Factors that might have influenced the occurrence of graft failure appear to be (1) the lack of radiotherapy in the conditioning regimen; (2) the conditioning regimen itself (fractionated total body irradiation [TBI], 12 Gy, vs. single dose is better than TBI, 10 Gy, but still not statistically significant); and (3) the age of the patients (high-risk after 30 years of age). In contrast, neither the number of nucleated cells reinfused nor the level of T-cell depletion (provided the T cells were below critical numbers) seemed to have an influence, nor did chemoprophylaxis for GVHD or splenectomy in chronic granulocytic leukemia (CGL) patients. The survival of graft failure patients was very poor (one of 11; survival at 15 months of the initial graft). Thus, our study demonstrates the reproducibility and high effectiveness in preventing GVHD by immunodepletion of T cells in a large-scale multicentric assay, in which compliance with the protocol of immunodepletion was reasonably good. This study thus provides interesting clues to overcoming graft rejection.This publication has 20 references indexed in Scilit:
- Level and temporal pattern of naturally cytolytic cells during acute Graft-versus-Host Disease (GVHD) in the ratCellular Immunology, 1983
- T CELL DEPLETION OF HUMAN BONE MARROW USING MONOCLONAL ANTIBODY AND COMPLEMENT-MEDIATED LYSISTransplantation, 1983
- Phenomenon of human T cells rosetting with sheep erythrocytes analyzed with monoclonal antibodies. "Modulation" of a partially hidden epitope determining the conditions of interaction between T cells and erythrocytesThe Journal of Experimental Medicine, 1982
- Bone marrow transplantation across major histocompatibility barriers in miceClinical Immunology and Immunopathology, 1982
- Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin.The Journal of Experimental Medicine, 1982
- ELIMINATION OF T‐LYMPHOCYTES FROM HUMAN BONE MARROW WITH MONOCLONAL T‐ANTIBODIES AND CYTOLYTIC COMPLEMENTBritish Journal of Haematology, 1982
- TRANSPLANTATION FOR ACUTE LEUKAEMIA WITH HLA-A AND B NONIDENTICAL PARENTAL MARROW CELLS FRACTIONATED WITH SOYBEAN AGGLUTININ AND SHEEP RED BLOOD CELLSThe Lancet, 1981
- An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells.The Journal of Experimental Medicine, 1980
- Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow.The Journal of Experimental Medicine, 1978
- Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins.Proceedings of the National Academy of Sciences, 1978